Standard BioTools Inc. Common Stock (LAB) Stock Price

LABStock

$0.63−51.24%52W

Market Cap$246.93M

P/E—

PEG Ratio—

Div yield—

Beta1.55

LAB Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-39.23%

Price vs S&P 500 (4W)-13.89%

VGM Score48.01

Book Value / Share (Quarterly)$1.38

P/TBV (Annual)1.47x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)-4.48%

Cash Flow / Share (Quarterly)$-0.21

Price vs S&P 500 (YTD)-62.79%

Gross Margin (TTM)50.49%

Net Profit Margin (TTM)100.37%

EPS (TTM)$0.22

10-Day Avg Trading Volume0.97M

EPS Excl Extra (TTM)$0.22

Revenue Growth (5Y)-9.18%

EPS (Annual)$-0.20

ROI (Annual)-29.41%

Gross Margin (Annual)49.86%

Net Profit Margin (5Y Avg)-95.42%

Cash / Share (Quarterly)$1.22

P/E Basic Excl Extra (TTM)2.91x

Revenue Growth QoQ (YoY)-7.62%

ROA (Last FY)-22.69%

Revenue Growth TTM (YoY)-45.15%

EBITD / Share (TTM)$-0.23

ROE (5Y Avg)-51.72%

Operating Margin (TTM)-112.85%

Cash Flow / Share (Annual)$-0.40

P/B Ratio0.46x

P/B Ratio (Quarterly)0.60x

Net Income / Employee (Annual)$-194,500

EV / Revenue (TTM)-0.27x

Net Interest Coverage (TTM)-15.25x

ROA (TTM)14.31%

EPS Incl Extra (Annual)$-0.20

Current Ratio (Annual)5.70x

Quick Ratio (Quarterly)8.67x

3-Month Avg Trading Volume2.30M

52-Week Price Return-51.24%

P/E Incl Extra (TTM)2.91x

Revenue / Employee (TTM)$219,700

Tangible BV / Share (Quarterly)$1.13

P/S Ratio (Annual)2.89x

Asset Turnover (Annual)0.28x

52-Week High$1.72

Operating Margin (5Y Avg)-86.05%

EPS Excl Extra (Annual)$-0.20

CapEx CAGR (5Y)-8.18%

26-Week Price Return-29.33%

Quick Ratio (Annual)4.94x

13-Week Price Return-29.71%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)9.10x

Enterprise Value$-22.79M

Revenue / Share Growth (5Y)-34.94%

Asset Turnover (TTM)0.14x

Book Value / Share Growth (5Y)29.38%

Revenue / Employee (Annual)$221,600

Inventory Turnover (Annual)1.49x

Pretax Margin (Annual)-113.33%

Cash / Share (Annual)$0.78

3-Month Return Std Dev57.85%

Gross Margin (5Y Avg)42.81%

Net Income / Employee (TTM)$220,500

ROE (Last FY)-29.42%

Net Interest Coverage (Annual)-15.25x

EPS Basic Excl Extra (Annual)$-0.20

Receivables Turnover (TTM)5.57x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$0.22

Receivables Turnover (Annual)5.75x

ROI (TTM)17.63%

P/S Ratio (TTM)2.92x

Pretax Margin (5Y Avg)-96.15%

Revenue / Share (Annual)$0.22

Tangible BV / Share (Annual)$1.17

Price vs S&P 500 (52W)-66.77%

P/E Ratio (TTM)2.91x

Year-to-Date Return-50.86%

5-Day Price Return-4.38%

EPS Normalized (Annual)$-0.20

ROA (5Y Avg)-26.47%

Net Profit Margin (Annual)-87.77%

Month-to-Date Return-15.07%

Cash Flow / Share (TTM)$-0.78

EBITD / Share (Annual)$-0.26

Operating Margin (Annual)-129.20%

LT Debt / Equity (Annual)0.02x

ROI (5Y Avg)-38.00%

P/E Excl Extra (TTM)2.91x

LT Debt / Equity (Quarterly)0.00x

EPS Basic Excl Extra (TTM)$0.22

P/TBV (Quarterly)0.96x

P/B Ratio (Annual)1.38x

Inventory Turnover (TTM)2.03x

Pretax Margin (TTM)-107.55%

Book Value / Share (Annual)$1.25

Price vs S&P 500 (13W)-32.40%

Beta1.55x

Revenue / Share (TTM)$0.22

ROE (TTM)17.64%

52-Week Low$0.63

vGradeA

gGradeD

mGradeC

vgmGradeC

LAB Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q2 2026	Aug 5, 2026	-$0.03	-$0.06	-100.00%(-$0.03)
Q1 2026	May 5, 2026	-$0.02	-$0.02	+15.50%(+$0.00)
Q4 2025	Feb 24, 2026	-$0.03	$0.07	+368.80%(+$0.09)
Q3 2025	Nov 4, 2025	-$0.02	-$0.04	-101.50%(-$0.02)
Q2 2025	Aug 11, 2025	-$0.04	-$0.04	+0.25%(+$0.00)

LAB Analyst Recommendations

Jun 2026

Jul 2026

Aug 2026

Sep 2026

4.00

Industry Peers — Pharmaceuticals(574)

Symbol	Value Score	Growth Score	Momentum Score	P/S Ratio (TTM)	Revenue Growth TTM (YoY)	Gross Margin (TTM)	EPS Growth (5Y)	Price
LABStandard BioTools Inc. Common Stock	A	D	C	2.9x	-45.1%	50.5%	—	$0.63
LLYEli Lilly & Co.	D	B	A	14.9x	49.6%	83.4%	27.6%	$1257.03
JNJJohnson & Johnson	D	C	B	6.2x	7.8%	67.7%	14.9%	$255.56
ABBVABBVIE INC.	D	C	A	7.8x	10.4%	72.8%	-2.9%	$285.42
MRKMerck & Co., Inc.	D	C	A	5.4x	4.6%	77.3%	21.2%	$145.95
NVSNovartis AG	C	C	B	4.9x	3.3%	75.0%	15.3%	$150.62
AZNAstraZeneca PLC	C	B	B	4.3x	8.6%	81.3%	21.9%	$165.41
ABTAbbott Laboratories	C	C	B	3.9x	8.1%	56.8%	8.2%	$104.89
NVONovo-Nordisk A/S	B	C	C	3.5x	5.6%	80.7%	20.7%	$38.83
PFEPfizer Inc.	C	D	A	2.6x	-0.2%	74.7%	-3.5%	$29.58
VRTXVertex Pharmaceuticals Inc	D	C	B	10.1x	10.2%	86.0%	8.3%	$499.74
BMYBristol-Myers Squibb Co.	B	B	B	2.5x	3.1%	71.7%	—	$59.75
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	C	C	B	2.3x	5.0%	73.6%	-0.5%	$49.51
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	D	B	1.8x	13.4%	72.8%	-8.2%	$40.61
REGNRegeneron Pharmaceuticals Inc	C	C	A	5.2x	9.3%	86.0%	6.3%	$790.74
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	A	2.1x	3.1%	65.5%	-12.6%	$19.67
TEVATeva Pharmaceutical Industries Limited	D	C	A	2.8x	4.1%	52.9%	—	$41.50
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	B	6.3x	31.1%	88.5%	—	$369.06
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	A	13.8x	10.0%	—	-12.1%	$60.96
ZTSZOETIS INC.	C	C	B	3.5x	1.4%	71.6%	12.0%	$79.38
ALNYAlnylam Pharmaceuticals, Inc.	D	A	C	6.5x	95.1%	79.7%	—	$231.83
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	3215.5x	-67.6%	81.2%	—	$33.53
UTHRUnited Therapeutics Corp	C	C	B	7.2x	2.5%	86.1%	19.3%	$533.12
GMABGenmab A/S ADS	D	C	A	5.5x	22.3%	93.0%	6.8%	$37.00
VTRSViatris Inc. Common Stock	B	C	A	1.5x	4.4%	40.3%	—	$18.66
INSMInsmed, Inc.	F	A	C	18.5x	185.8%	83.5%	—	$96.27
ASNDAscendis Pharma A/S Ordinary Share	D	A	B	11.9x	113.3%	91.3%	—	$225.25
JAZZJazz Pharmaceuticals, Inc.	B	C	B	3.0x	12.6%	88.4%	-1.4%	$210.23
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	18.2x	202.4%	94.4%	—	$66.39
CORTCorcept Therapeutics Inc.	F	C	A	14.3x	16.0%	98.3%	-0.5%	$110.16
ELANElanco Animal Health Incorporated Common Stock	D	B	B	2.3x	11.9%	55.4%	29.9%	$23.55
SMMTSummit Therapeutics Inc. Common Stock	F	—	C	12187.5x	—	—	—	$14.63
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	C	B	3.1x	-0.9%	61.4%	16.5%	$13.07
BMRNBioMarin Pharmaceuticals Inc	C	C	B	3.1x	11.2%	79.6%	-17.0%	$54.68
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	C	8.1x	149.0%	91.5%	—	$449.74
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	213.8x	2928.4%	—	—	$84.95
CYTKCytokinetics Inc.	F	D	B	127.3x	-21.1%	—	—	$61.95
PTGXProtagonist Therapeutics, Inc	F	B	B	29.5x	34.8%	—	—	$128.75
TGTXTG Therapeutics, Inc.	D	B	B	10.3x	76.1%	82.4%	—	$53.97
AXSMAxsome Therapeutics, Inc	D	B	C	10.6x	56.9%	93.2%	—	$157.14
ARWRArrowhead Research Corporation	D	A	C	11.8x	16.9%	—	—	$55.90
ABVXAbivax SA American Depositary Shares	—	—	C	—	—	—	—	$88.13
SYRESpyre Therapeutics, Inc. Common Stock	—	—	B	5995.2x	—	—	—	$79.90
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	8.2x	-7.5%	98.2%	—	$42.94
ALKSAlkermes Inc. plc	D	C	B	4.1x	10.8%	84.6%	—	$41.22
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	789.2x	—	—	—	$241.76
AMRXAmneal Pharmaceuticals, Inc. Class A Common Stock	D	C	A	2.0x	9.3%	39.3%	-18.4%	$19.18
KNSAKiniksa Pharmaceuticals International, plc Class A Ordinary Shares	D	B	A	7.3x	58.9%	89.8%	—	$78.59
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	24.7x	53.5%	70.9%	—	$86.17
LGNDLigand Pharmaceuticals Inc.	D	B	B	20.3x	54.9%	95.4%	—	$295.54
BLTEBelite Bio, Inc American Depositary Shares	—	—	B	—	—	—	—	$142.78

About Standard BioTools Inc. Common Stock

Standard BioTools develops and manufactures advanced analytical instruments for biomedical research, primarily using mass cytometry and microfluidics technologies to accelerate drug discovery. The company operates two core segments—Proteomics and Genomics—with Proteomics representing the largest revenue contributor. Its solutions enable researchers to gain deeper insights into health and disease mechanisms, supporting faster therapeutic development. The company generates the majority of its revenue from the Americas.